|
مقاله
|
Abstract
|
|
|
|
Title:
|
Intravitreal injection of methotrexate in persistent diabetic macular edema; a six-month follow up study.
|
|
Author(s):
|
Khalil Ghasemi Falavarjani, Mehdi Modarres, Mohammad Mehdi Parvaresh, Masih Hashemi, Masood Naseripour, Sara Golabi
|
|
Presentation Type:
|
Oral
|
|
Subject:
|
Posterior Segment and Uveitis
|
|
Others:
|
|
|
Presenting Author:
|
|
|
Name:
|
Khalil Ghasemi Falavarjani
|
|
Affiliation :(optional)
|
Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences
|
|
E mail:
|
drghasemi@yahoo.com
|
|
Phone:
|
|
|
Mobile:
|
09121725850
|
|
|
|
|
Purpose:
|
To evaluate the efficacy of intravitreal methotrexate (MTX) in persistent diabetic macular edema (DME) nonresponsive to intravitreal bevacizumab.
|
|
Methods:
|
In this prospective, interventional study, intravitreal injection of 400 µg MTX was performed in eyes with persistent center-involving DME. BCVA, central subfield thickness (CST) and maximum retinal thickness (MRT) were recorded before and 1, 3, and 6 months after injections.
|
|
Results:
|
Eighteen eyes of 16 patients were included. The mean change in BCVA was -0.09±0.19, -0.1±0.19 and -0.1±0.19 LogMAR at 1, 3 and 6 months after intravitreal MTX injections, respectively (P=0.05, P=0.04, and P=0.04, respectively).
Mean change in CST was -23.7±66.7, -28.7±82.2 and 26.5±83.4 µm at 1, 3 and 6 months after MTX injections, respectively (all P=0.1). A decrease in CST was found in 13 eyes (72.2%) at 1 and 3 months, and 7 eyes (38.8%) at 6 months of follow up. Mean change in MRT was -35.1±76.4, -40.6±86.3 and 29.8±68.6 µm at 1, 3 and 6 months after MTX injections, respectively (P=0.06, P=0.06 and P=0.08, respectively).
|
|
Conclusion:
|
In this study, intravitreal injection of MTX resulted in anatomical improvement in a significant proportion of eyes with persistent DME. Significant visual improvement was found in 16.6% of eyes.
|
|
Attachment:
|
|
|